Immuron Limited (FRA:ANW)

Market Cap	7.43M -26.9%
Revenue (ttm)	4.25M +14.3%
Net Income	-2.64M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0145
Previous Close	0.0175
Day's Range	0.0145 - 0.0145
52-Week Range	0.0070 - 0.0445
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 28, 2026

About Immuron

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, the United States, and Canada. It operates through two segments, Research and Development; and Hyper-immune Products. The company offers Travelan, an over-the-counter medicine to reduce the risk of travelers’ diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for digestive tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive func...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1994
• Employees: 7
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: ANW

Financial Performance

In fiscal year 2025, Immuron's revenue was 7.29 million, an increase of 48.63% compared to the previous year's 4.90 million. Losses were -5.22 million, -24.81% less than in 2024.

Financial numbers in AUD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Aug 27, 2026

Data Sources Report a data error